查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878823

分子製藥市場－全球產業規模、佔有率、趨勢、機會和預測，依作物來源、技術、應用、最終用戶、地區和競爭格局分類，2020-2030年預測

Molecular Pharming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Crop Source, By Technology, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球分子製藥市場規模為25.6億美元，預計2030年將以8.00%的複合年成長率成長至40.6億美元。分子製藥是指透過基因工程改造植物、動物或微生物，使其成為生產藥物蛋白、疫苗和其他重要治療化合物的生物反應器。市場成長的主要驅動力是消費者對具成本效益生物製藥產品的需求不斷成長，以及基因工程技術的持續進步提高了生產效率和產量。分子製藥平台固有的可擴展性和適應性也顯著促進了其市場擴張。

市場概覽
預測期 2026-2030
2024年市場規模 25.6億美元
2030年市場規模 40.6億美元
2025-2030年複合年成長率 8%
成長最快的細分市場 生物技術和製藥公司
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球分子製藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依作物來源分類（玉米、大麥、菸草、紅花、稻米、苜蓿）
    • 依技術分類（基因槍、農桿菌侵染、電穿孔、農桿菌介導的基因轉殖、其他）
    • 依應用領域（重組抗體、荷爾蒙、疫苗、工業酵素、蛋白質及蛋白質基材料、技術試劑、營養作物來源、其他）
    • 按最終用戶（生物技術和製藥公司、合約生產組織、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美分子製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲分子製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太分子製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲分子製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲分子製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球分子製藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Agrenvec SL
  • Diamante SRL
  • Leaf Systems International Limited
  • Medicago Inc
  • Meristem Therapeutics SA
  • Moolec Science SA
  • ORF Genetics
  • Pfizer, Inc.
  • ProdiGene Inc
  • Protalix Biotherapeutics, Inc.

第16章：策略建議

第17章調查會社について,免責事項

\

簡介目錄
Product Code: 7873

The Global Molecular Pharming Market, valued at USD 2.56 Billion in 2024, is projected to experience a CAGR of 8.00% to reach USD 4.06 Billion by 2030. Molecular pharming involves the genetic engineering of plants, animals, or microorganisms to serve as bioreactors for producing pharmaceutical proteins, vaccines, and other valuable therapeutic compounds. The market's growth is primarily driven by the increasing demand for cost-effective biopharmaceuticals, coupled with continuous advancements in genetic engineering techniques that enhance production efficiency and yield. The inherent scalability and adaptability of molecular pharming platforms also contribute significantly to its expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.56 Billion
Market Size 2030USD 4.06 Billion
CAGR 2025-20308%
Fastest Growing SegmentBiotechnology & Pharmaceutical Companies
Largest MarketNorth America

Key Market Drivers

The Global Molecular Pharming Market is significantly propelled by continuous advancements in genetic engineering technologies. These innovations enable increasingly precise and efficient modification of organisms for pharmaceutical protein production, fostering the development of novel therapeutic compounds and enhancing production yields. For instance, according to Labiotech. eu, September 30, 2025, "CRISPR technology's next wave: Ten companies to watch in 2025", Chroma, a company building an epigenetic editing platform, secured $135 million in Series B funding in 2023, highlighting substantial investment directed towards refining gene-editing capabilities that underpin molecular pharming applications. Such technological progress, including advanced gene-editing tools and synthetic biology techniques, is crucial for overcoming previous limitations in expression levels and product quality, thereby expanding the feasibility and commercial viability of molecular pharming systems across various platforms like plants and microbial hosts.

Key Market Challenges

A significant challenge impeding the growth of the Global Molecular Pharming Market is the complex regulatory landscape and the stringent approval processes governing genetically modified organisms and their derived products, along with concerns regarding potential environmental contamination risks. This intricate web of regulations directly impacts market expansion by extending the time required to bring novel biopharmaceuticals to market and increasing associated development costs.

The extensive testing, data collection, and sequential regulatory hurdles for genetically modified products, including those produced through molecular pharming, contribute to a prolonged and costly approval pathway. According to EFPIA's 2024 Key Data, an average of 12-13 years elapses from the first synthesis of a new active substance until it reaches the market. This extended timeline delays the commercialization of products and the generation of revenue, thereby diminishing the attractiveness of investing in molecular pharming initiatives. The uncertainty and high capital expenditure linked to navigating these demanding regulatory environments make it more difficult for companies to secure funding and allocate resources to the development of pharming-derived therapeutics, consequently hampering overall market growth.

Key Market Trends

The Global Molecular Pharming Market is experiencing a notable shift due to the diversification of its applications into nutraceutical production. This trend highlights the expansion of molecular pharming beyond traditional pharmaceutical proteins into generating high-value compounds for the functional food and dietary supplement industries. The inherent scalability and cost-effectiveness of molecular pharming platforms, particularly plant-based systems, are well-suited for producing vitamins, antioxidants, and other health-promoting substances, addressing a rising consumer demand for natural and bio-enhanced products. According to the Council for Responsible Nutrition, in 2024, 75% of Americans continued to use dietary supplements, demonstrating sustained consumer interest. This consistent demand propels molecular pharming companies to explore new revenue streams.

Key Market Players

  • Agrenvec S.L
  • Diamante SRL
  • Leaf Systems International Limited
  • Medicago Inc
  • Meristem Therapeutics S.A.
  • Moolec Science SA
  • ORF Genetics
  • Pfizer, Inc.
  • ProdiGene Inc
  • Protalix Biotherapeutics, Inc.

Report Scope:

In this report, the Global Molecular Pharming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Pharming Market, By Crop Source:

  • Maize
  • Barley
  • Tobacco
  • Safflower
  • Rice
  • Alfalfa

Molecular Pharming Market, By Technology:

  • Gene Gun
  • Agroinfiltration
  • Electroporation
  • Agrobacterium-Mediated Gene Transfer
  • Others

Molecular Pharming Market, By Application:

  • Recombinant Antibodies
  • Hormones
  • Vaccines
  • Industrial Enzymes
  • Proteins & Protein-Based Materials
  • Technical Reagents
  • Nutritional Crop Sources
  • Others

Molecular Pharming Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Others

Molecular Pharming Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Molecular Pharming Market.

Available Customizations:

Global Molecular Pharming Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Pharming Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Crop Source (Maize, Barley, Tobacco, Safflower, Rice, Alfalfa)
    • 5.2.2. By Technology (Gene Gun, Agroinfiltration, Electroporation, Agrobacterium-Mediated Gene Transfer, Others)
    • 5.2.3. By Application (Recombinant Antibodies, Hormones, Vaccines, Industrial Enzymes, Proteins & Protein-Based Materials, Technical Reagents, Nutritional Crop Sources, Others)
    • 5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Contract Manufacturing Organizations, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Molecular Pharming Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Crop Source
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Molecular Pharming Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Crop Source
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Molecular Pharming Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Crop Source
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Molecular Pharming Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Crop Source
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Molecular Pharming Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Crop Source
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Molecular Pharming Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Crop Source
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Molecular Pharming Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Crop Source
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Molecular Pharming Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Crop Source
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Molecular Pharming Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Crop Source
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Molecular Pharming Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Crop Source
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Molecular Pharming Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Crop Source
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Molecular Pharming Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Crop Source
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Molecular Pharming Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Crop Source
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Molecular Pharming Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Crop Source
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Molecular Pharming Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Crop Source
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Molecular Pharming Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Crop Source
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Molecular Pharming Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Crop Source
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Molecular Pharming Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Crop Source
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Molecular Pharming Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Crop Source
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Molecular Pharming Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Crop Source
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Molecular Pharming Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Crop Source
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Molecular Pharming Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Crop Source
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Molecular Pharming Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Crop Source
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Molecular Pharming Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Crop Source
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Molecular Pharming Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agrenvec S.L
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Diamante SRL
  • 15.3. Leaf Systems International Limited
  • 15.4. Medicago Inc
  • 15.5. Meristem Therapeutics S.A.
  • 15.6. Moolec Science SA
  • 15.7. ORF Genetics
  • 15.8. Pfizer, Inc.
  • 15.9. ProdiGene Inc
  • 15.10. Protalix Biotherapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

\